30 Jul 2020 by admin in UncategorizedComments resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Result
28 Jul 2020 by admin in UncategorizedComments resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults
22 Jun 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH THE COMBINATION OF TPST-1120 PLUS NIVOLUMAB IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS
28 May 2020 by admin in UncategorizedComments resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents
07 May 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TPST-1495 CLINICAL STUDY: DUAL EP2/4 ANTAGONIST TARGETING SOLID TUMORS
07 May 2020 by admin in UncategorizedComments resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial Results
07 May 2020 by admin in UncategorizedComments Syros Reports First Quarter 2020 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
05 May 2020 by admin in UncategorizedComments Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic
